-84%

est. 2Y upside i

HealthcareSeries B

Rank

#3626

Sector

Oral Healthtech

Est. Liquidity

~5Y

Data Quality

Data: Low

Due to missing financial data, equity analysis is highly speculative.

Last updated: July 19, 2026

Bull (20%)-61%

Exit multiple holds at 5x due to category leadership via strong moat and FDA clearance. Projected revenue of $8.8M yields exit value $44M, but after 20% dilution upside is -61.3% from $75M entry.

Base (55%)-85%

Multiple converges to comp range of 3x, exit value $26.4M. After 20% dilution, upside -84.8%. Stale valuation and missing fundamentals weigh.

Bear (25%)-100%

Multiple compresses to 1.5x, exit value $13.2M below $15M preference stack; common stock recovers -100%.

Est. time to liquidity~5.0 years

Preference Stack Risk

moderate

Funding Intensity

20%

Total funding $15M against assumed valuation $75M (20% overhang); bear case exit below $15M wipes out common stock.

Dilution Risk

high

No recent funding, likely need capital within 12-18 months; estimated 20% dilution from future raise.

Secondary Liquidity

none

No secondary market activity; shares are illiquid until IPO or acquisition.

Questions to Ask at the Interview

Strategic questions based on Proclaim's data — designed to show you've done your homework.

  • 1

    “What is your current annual recurring revenue (ARR) and year-over-year growth rate?”

  • 2

    “How do you plan to defend against Oral-B and Philips entering your niche?”

  • 3

    “What is your expected cash runway and do you plan to raise within 24 months?”

Community

Valuation Sentiment

Our model estimates -84% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.